These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27885314)

  • 1. In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.
    Shashikant L; Kesterson Joshua P
    J Obstet Gynaecol India; 2009; 59(3):209-216. PubMed ID: 27885314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature.
    Papadia A; Morotti M
    Arch Gynecol Obstet; 2013 Apr; 287(4):733-41. PubMed ID: 23341061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
    Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of aggressive surgical cytoreduction in advanced ovarian cancer.
    Chang SJ; Bristow RE; Chi DS; Cliby WA
    J Gynecol Oncol; 2015 Oct; 26(4):336-42. PubMed ID: 26197773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive surgery in the management of ovarian cancer.
    Schwartz PE
    Oncology (Williston Park); 2008 Aug; 22(9):1025-33; discussion 1033-8, 1041, 1045. PubMed ID: 18777954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
    Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.
    Eggink FA; Mom CH; Kruitwagen RF; Reyners AK; Van Driel WJ; Massuger LF; Niemeijer GC; Van der Zee AG; Van der Aa MA; Nijman HW
    Gynecol Oncol; 2016 Jun; 141(3):524-530. PubMed ID: 27090157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Cordeiro Vidal G; Babin G; Querleu D; Guyon F
    Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF; Li MD; Liu FY; Liu JH; Li JD
    Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with cytoreducibility among women with ovarian carcinoma.
    Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K; Morgan A
    Gynecol Oncol; 2004 Nov; 95(2):377-83. PubMed ID: 15491760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature.
    Bristow RE; Lagasse LD; Karlan BY
    Cancer; 1996 Nov; 78(10):2049-62. PubMed ID: 8918397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.
    Pelissier A; Roulot A; Guéry B; Bonneau C; Bellet D; Rouzier R
    J Ovarian Res; 2016 Sep; 9(1):61. PubMed ID: 27677313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
    Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.
    Everett EN; French AE; Stone RL; Pastore LM; Jazaeri AA; Andersen WA; Taylor PT
    Am J Obstet Gynecol; 2006 Aug; 195(2):568-74; discussion 574-6. PubMed ID: 16890558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
    Eisenkop SM; Spirtos NM
    Gynecol Oncol; 2001 Sep; 82(3):489-97. PubMed ID: 11520145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
    Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
    Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant chemotherapy for advanced epithelial ovarian cancer].
    Hatae M; Onishi Y; Nakamura T; Yamamoto H; Kusumoto M; Matsui T; Mihara K; Taniguchi H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1833-7. PubMed ID: 11729475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.